Key Takeaways
- Strong quarter, broad-based domestic engine: Revenue grew 14% YoY to ₹963 cr, with India formulations surging 22% and now contributing 60% of the top line. Net profit jumped 22% to ₹162 cr.
- The portfolio transformation is working: The progressive portfolio now makes up 65% of domestic revenue, up from 35% four years ago, and 25 brands exceed ₹25 cr in sales, up from just 6 in December 2020.
- CDMO is the second growth engine: The business grew 33% YoY to ₹118 cr, with two new European partners onboarded and 4-5 big global projects visible over the next 18-24 months.
- Margins expanded despite a dilutive acquisition: Operating EBITDA margin improved ~80 bps in 9M FY25 even as the ophthalmology portfolio dragged gross margins by 150-160 bps; the base business implied 200-250 bps of EBITDA margin expansion.
- What to watch next quarter: Whether the promised double-digit international growth in Q4 materializes, the pace of ophthalmology margin improvement from its current ~20% gross margin toward 70%, and any upward revision to the 26-28% EBITDA margin guidance.
Domestic Formulations: The Volume-Led Engine
- Outpacing the market: India business grew 12% YoY versus IPM growth of 8%, making JB one of the fastest-growing companies in the market. Growth is volume-driven, with price growth capped at 7-8% beyond a certain point.
- Progressive portfolio shift: 65% of domestic revenue now comes from a portfolio growing faster than IPM, spanning cardiology, pediatrics, probiotics, and Metrogyl. This mix change is expected to enable consistent growth over the next few years.
- Brand depth transformation: In December 2020, only 6 brands exceeded ₹25 cr; by December 2024, 25 brands crossed that threshold, with five ranking in the top 150 nationally. Over the next 2-3 years, 10-12 brands are expected to inch toward a ₹50 cr run rate.
- Field force stable: No plans to increase the medical rep count in the next 12-15 months; the current deployment is considered adequate.
Kunal Khanna: "Yes, it's a reflection of, you know, not only our Ophthal but even our overall India business and even Ophthal is absolutely volume driven. See, because beyond a certain point, there is no real opportunity for us to take price growth beyond 7 to 8%, right? So, it's volume driven."
Cilacar Franchise & Cardiology Strategy
- Beyond hypertension: The franchise targets hypertension with comorbidities through a full portfolio of Cilnidipine combinations: with Metoprolol for angina, Azmarda for heart failure, Razel for high lipids, and Telmisartan for metabolic conditions. The stated objective is to reduce disease burden for patients with hypertension and comorbidities.
- Cilacar-T as first-line therapy: In complicated diabetic hypertension, RSSDI guidelines specify CCB plus ARB as first-line treatment, with Cilnidipine as the preferred molecule within the CCB class. Management's ambition is for Cilacar-T to become a ₹1,000 cr product.
- Azmarda gaining traction: Units per month are growing sequentially by 15-20,000, with positive visibility and trends.
- Cardiology depth over breadth: The company will stick to its cardiology domain (hypertension, heart failure, lipids) and may expand into arrhythmias or blood thinners. It will not pursue metabolic or diabetes organically after past attempts with Sitagliptin, Vildagliptin, and Dapagliflozin faced intense competition. Inorganic opportunities in related areas will be evaluated.
Nikhil Chopra: "So, we have a whole range of portfolio and this is not only that we are going and talking in the clinic and generating value, but overall the objective is how to reduce the burden of disease for the patients who are suffering from hypertension and comorbidities. So, that is the task that we have taken. That is why you see the entire differential that we as a company bring on the table as compared to other companies."
Ophthalmology: Early-Stage Volume Ramp
- Strong growth off a small base: The ophthalmology portfolio grew 28%+ against a market growing at ~9%. Growth is entirely volume-driven, with a 15-20% increase in prescription uptake and secondary-market units sold.
- Coverage expansion underway: A dedicated field force of ~120 people has been deployed, nearly doubling ophthalmologist coverage from 7,000 to 14-15,000. One new product was added in the last two months, with one or two SKUs planned every quarter over the next 6-8 months.
- Margin drag today, tailwind tomorrow: The acquired portfolio currently carries gross margins of ~20%, diluting company-level gross margins by 150-160 bps. Management expects this to improve to 70% over time, contributing a 200 bps uplift to overall EBITDA. The timeline for this improvement remains vague.
CDMO: The Second Growth Pillar
- 33% growth and new partners: CDMO revenue reached ₹118 cr in Q3. Two new European partners were added: Krka in the Czech Republic (lozenge supply already started) and Kenvue, the consumer arm of J&J, for lozenges under the Zarbees brand for immunity and wellness in Europe.
- Project pipeline building: Management sees good visibility of 4-5 big global projects kicking in over the next 18-24 months, spanning newer formulations and geographies beyond Europe. All associated CAPEX has already been put in place at the Daman and Panoli plants, with developmental work ongoing. The CAPEX quantum is absorbable within regular expansion and maintenance budgets.
- Q4 order book strong: The CDMO business is expected to deliver a strong Q4, with new projects, new geographies, and new therapeutic dosage forms contributing. The business is tracking at mid-teens growth for the short to medium term.
International Formulations: Mixed, with Q4 Promise
- Overall international up 4%: Revenue reached ₹397 cr, with CDMO strength offsetting weakness in US and Russia. South Africa and the branded generic business showed growth.
- Russia: currency and season, not structural: Constant-currency decline was minus 5% versus minus 8% reported. A muted cough-and-cold season in November-December and currency volatility drove the softness; the first six months were phenomenally strong, and nothing has structurally changed.
- US inching back: The first six months were slightly soft, but the business is expected to be back on track.
- Q4 bullishness: Management expects double-digit growth in international business in Q4, driven by a strong CDMO order book. India may see some softness from March inventory destocking, but overall traction is maintained and the year is expected to end on a high note.
Margins & Capital Allocation
- Margin expansion despite dilution: Operating EBITDA margin improved ~80 bps in 9M FY25 to 28%, even as the ophthalmology acquisition dragged gross margins by 150-160 bps. On the base business, implied EBITDA margin expansion was 200-250 bps, driven by cost optimization, favorable product mix, and pricing growth.
- Gross margin range holds: Gross margins are expected to continue in the 66-67% range at the yearly level. Some challenges exist from essential-pharma-index and forex impacts, but the company is adequately covered with stock and confident of the range. Q4 should be close to current margins.
- Debt-free milestone: The company will pay off all loans and become debt-free. A dividend was announced.
- Inorganic appetite intact: The company continues to evaluate assets that are synergistic, in line with existing categories, offer a good payback period, and are quality assets in growing markets. It wants to acquire something long-lasting and will not ignore new therapy areas if the asset quality is right.
Nikhil Chopra: "You always will see Rahul, us being, what guidance we have been giving, of 26 to 28% probably we will be ending the year on a higher note on the higher side of the guidance... At the right time, we will be more than happy to revise our guidelines, which touch wood should be on the upward trajectory only."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Operating EBITDA margin | 26% to 28% range; ending FY25 on the higher side; open to upward revision | FY25 exit / "at the right time" |
| India business growth | Mid-teens growth backed by strong volume growth | Ongoing (Q4 onwards includes ophthalmology base) |
| International business growth | Double-digit growth in Q4; high single-digit to double-digit medium term | Q4 FY25 / medium term |
| CDMO business growth | Mid-teens growth; strong Q4 order book | Short to medium term |
| Ophthalmology SKU launches | One or two new SKUs added every quarter | Next 6-8 months |
| Ophthalmology margin improvement | Gross margin from ~20% to 70%, adding 200 bps to overall EBITDA | Vague timeline |
| CDMO big projects | 4-5 big global projects kicking in; CAPEX already placed | 18-24 months visibility |
| Brand pipeline | 10-12 brands inching toward ₹50 cr run rate | Next 2-3 years |
| Cilacar-T ambition | Become a ₹1,000 cr product | Foreseeable future |
| India + CDMO revenue contribution | Move from 72% to 80% of total revenue | Short to medium term |
| Debt-free status | All loans paid off | Imminent |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹963 cr, +14% YoY |
| Operating EBITDA | ₹270 cr, +15% YoY |
| Operating EBITDA margin | 28.1%, improved from 27.6% in Q3 FY24 (per an analyst's math) |
| Net profit | ₹162 cr, +22% YoY |
| Gross margin | 67.1%, vs 67.6% in Q3 FY24 |
| Gross margin ex-ophthalmology | Improved 160 bps YoY and at YTD level |
| Domestic business revenue | ₹566 cr, +22% YoY |
| Domestic business growth vs IPM | 12% YoY vs IPM growth of 8% |
| Domestic volume growth ex-ophthalmology | 7% for Q3 FY25, 6% for 9-month FY25 |
| International business revenue | ₹397 cr, +4% YoY |
| CDMO business revenue | ₹118 cr, +33% YoY |
| Finance costs | ₹3 cr, down from ₹12 cr in Q3 FY24 |
| Depreciation | ₹42 cr, same as previous quarter |
| Gross debt | ₹54 cr as of 30th Dec 2024 |
| Net cash | ₹516 cr as of 30th Dec 2024 |
| ESOP cost FY25 full-year expected | ₹56 cr, with ₹16 cr in Q4 FY25 |
| MTM forex loss | ₹4 cr, primarily from ruble depreciation |
| Russia constant currency growth | -5% vs -8% reported |
| Ophthalmology portfolio growth | 28% plus vs market growth of close to 9% |
| Top 5 domestic brands contribution | 60-65% of overall India business, down from over 75% in FY20 |
| Brands with revenue >₹25 cr | 25 brands, up from 6 in December 2020 |
| Azmarda monthly unit trend | ~130,000 units per month, up from 95-100,000 five to six months ago |
| Sporlac revenue | More than ₹120 cr (IQVIA MAT reflection) |
| EBITDA margin guidance | 26% to 28%, expected to end FY25 close to 28% |
| India + CDMO revenue contribution | 72% of total revenue, up from 50% four years ago |